Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. - Wikidata - awgldk - TriplyDB

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.

http://www.wikidata.org/entity/Q36622433

about

Targeted therapies in sarcomas: challenging the challenge Pazopanib in the management of advanced soft tissue sarcomas Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas Pazopanib, a new therapy for metastatic soft tissue sarcoma The evolution of systemic therapy in sarcoma.Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.Pazopanib: approval for soft-tissue sarcoma.Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues.Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis.Targeted therapy in sarcomas other than GIST tumors Prognostic significance of Minichromosome maintenance protein 7 and Geminin expression in patients with 109 soft tissue sarcomas.Anti-angiogenic treatment of gastrointestinal malignancies.Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma TNP-470 Suppresses the Tumorigenicity of HT1080 Fibrosarcoma Tumor Through the Inhibition of VEGF Secretion From the Tumor Cells.Emerging drugs for the treatment of soft tissue sarcomas.Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).Pazopanib: an antiangiogenic drug in perspective.Targeting angiogenesis in childhood sarcomas.Systemic management strategies for metastatic soft tissue sarcoma.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.Soft tissue sarcoma in the dog - Part 2: surgical margins, controversies and a comparative review.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Soft tissue sarcoma in the dog - part 1: a current review.Pharmacological therapies for Liposarcoma.Newer medical therapies for metastatic soft tissue sarcoma.Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.von Willebrand factor expression in osteosarcoma metastasis.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.Endothelial hyperplasia: an important indicator of actual angiogenesis.

P2860

Q21285014-751F57A5-735C-41F9-BF7B-DE9C4A93571B Q26746205-3E7B707E-7CEF-411A-8971-D66BDE447516 Q26825000-B9C7C1E6-474C-4CE6-9756-7F8D5D64A032 Q28287163-102FBC01-149E-4C96-B4D5-B7148EC982C1 Q33274710-133FCE6B-CF4C-4185-B595-0202A5965337 Q33680274-00812B0C-8E27-4E2B-82A1-B10886B0408C Q33778580-5AD1765F-6994-46C7-B934-47120053B0F2 Q33885782-AA2CF700-F760-431E-AF45-0C3CA48032E9 Q34129496-6719A12F-FE91-4B06-9E44-AF075271D7E3 Q35165994-670F666D-61EA-4E56-93B0-ACBB858A0847 Q35206566-09BAB4B1-E429-414B-87BA-811BC3BE7917 Q35235635-D86F3B68-99E0-4034-81D2-A2194A4D4CC5 Q35622367-8B590C6A-A7E9-47F2-B969-11590CF34A8C Q36216959-9FF9B9FD-8B9B-4AB4-8FF7-3CC7F101C4DD Q36353516-C3B63245-4F10-42B3-AD80-AD48A46C0AE6 Q36623745-D0B76C7B-E0DA-4FC2-B4DF-FCB9E6D06319 Q36674104-37797CB2-9CB5-40EC-8752-751D84E66AFA Q36758596-DF137A9A-989D-4E92-A4FC-F3EF107555F5 Q36819466-9B3E3228-2DE9-4CD7-B9DD-3AF8C4375169 Q37181235-EBFD2B78-F487-46C2-BF27-33C48F11D15E Q37190323-F1225E2D-C10C-4CF3-8E1E-C11BD0BA95AD Q37269236-8FCF9881-BFFB-43E1-A6F2-20F99B50FABC Q37502192-280A7A44-6C03-454B-B835-8191E4C2EFA7 Q37619835-6BA3DC0B-782F-4CA7-A36D-9AEF49A633C9 Q37630567-F5A7B418-CE4B-46E6-AE07-E42CBE0099BB Q37825441-286F5A56-7B0C-46FB-AB1C-F1CF21967E8F Q37950516-AFB82EBA-ECB7-4E36-9F07-CE8FE9DFE2DB Q38252537-53A44532-16DC-4126-BB5F-36D4CF84D89E Q38569799-7AA4411E-5113-48AD-93CE-F79FB80087F3 Q38761697-22DA406F-8C2E-4B3C-9BCA-144C56D54205 Q38936104-C1A2C683-FCA6-41B1-84DC-A4306DAE9385 Q38953742-DB4668CB-3A97-4C1E-805D-9080A5E72486 Q38991731-8B6E3033-FD53-466A-B4BB-AD8977108A6B Q39012067-6E1A1F62-8CD6-4104-BB44-D69C9B66DB0A Q39501053-92BA84F5-338C-4947-9948-999FFF993C87 Q40507472-89220B01-E3AD-4C96-BDAE-E94E09DBE40E Q41105379-47217C75-A880-4326-8A19-BD080E8E2682 Q41953545-65927690-9DA8-47F8-8359-CA8B81F73F01 Q42712126-E5BECB93-A8CE-4847-AB4E-4C35635B7AA5 Q42941413-858A333E-DF5E-4BEA-A530-18595383C04F

P2860

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.

http://www.wikidata.org/entity/Q36622433

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@ast

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@en

type

label

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@ast

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@en

prefLabel

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@ast

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@en

P1433

Q36622433-DC44F62A-88D6-403E-AFFC-17B87C461801

P1476

Q36622433-195F78BD-CABD-4A70-82D3-66E412A8EE0B

P2093

Q36622433-1CB056E3-B2B5-410C-8F91-EB1B4673C5C8

Q36622433-31D7B7FB-CADF-4F44-897B-D56311CD18FE

Q36622433-73D8D4D3-4658-488A-8C37-70A32DA95255

Q36622433-83754B9F-C860-45F5-9C5C-7A53469CED27

Q36622433-8FDDB9BB-1E2A-42C2-A465-990233DBB67B

Q36622433-AB8DA43A-C163-48A3-B615-25745028E533

P2860

Q36622433-216784EE-194E-441B-B52F-8FAB7481A602

Q36622433-2FA04A10-F603-4BE1-A539-B395A821831B

Q36622433-476D6931-412B-4FC1-9405-412746A19794

Q36622433-5E28FA29-9027-48AE-B722-E2DAF38518F6

Q36622433-657ADD4E-1A2C-4264-B4F6-BC04AEAB29BE

Q36622433-6814D63E-CBE7-4A63-A642-411B2EB66CF8

Q36622433-7CA2D913-4AEF-46AB-B0AF-8DE2800677FD

Q36622433-86717448-B1DB-41F1-B894-BE636EBBFB54

Q36622433-8FDECC53-E5B3-4810-B4C1-7CB4858520EA

Q36622433-9C8B7A62-0D99-48BB-9100-E8602AAF2C40

P2888

Q36622433-71F3C973-3CD7-4313-A162-D39F4DDE62D0

P304

Q36622433-F1331F0C-3DCA-4826-B5EB-D784567C8DCC

P31

Q36622433-3D1B14CA-617F-4E55-861D-BE6C4CD604C2

P356

Q36622433-05C9688E-F72D-44FE-B35A-E1F3ED694A44

P407

Q36622433-BD901968-92A2-42F5-8674-7C9FBF14561B

P433

Q36622433-06DB2945-4413-4722-AD2C-10B1153066EC

P478

Q36622433-A189233D-3479-482C-B0CC-B4BD089B127D

P577

Q36622433-D52701BC-02D2-49DD-8BB7-19E4D47CBD29

P5875

Q36622433-7B4EB370-0E8F-4215-B0F7-723ED560205D

P6179

Q36622433-592C4072-7F05-424E-85AC-4ED1A03A7CFA

P698

Q36622433-F3B4C173-C3CB-4986-86A7-6DAA11C844AA

P921

Q36622433-F254F674-AA59-4587-BBD5-514E50956E07

P932

Q36622433-3F187BA8-BF9B-4BC2-8993-091B003C5B21

P356

P1433

British Journal of Cancer

P1476

Concentration of vascular endo ...... actor of soft tissue sarcomas.

@en

P2093

Aoki M

http://www.w3.org/2001/XMLSchema#string

Kanamori M

http://www.w3.org/2001/XMLSchema#string

Kimura T

http://www.w3.org/2001/XMLSchema#string

Ohmori K

http://www.w3.org/2001/XMLSchema#string

Yasuda T

http://www.w3.org/2001/XMLSchema#string

Yudoh K

http://www.w3.org/2001/XMLSchema#string

P2860

What is the evidence that tumors are angiogenesis dependent?

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

Tumor dormancy in vivo by prevention of neovascularization.

Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases.

P2888

P304

1610-1615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2001.1837

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11938986

http://www.w3.org/2001/XMLSchema#string

P6179

1039075594

http://www.w3.org/2001/XMLSchema#string

P698

11401313

http://www.w3.org/2001/XMLSchema#string

P921

P932

2363691

http://www.w3.org/2001/XMLSchema#string